Loading... Please wait...

European Point of Care Diagnostic Testing Markets

Bookmark and Share
Price:
$3,400.00
Publication Date:
September 2011; Pages: 179
File Type:
Downloadable PDF


Description


European Point of Care Sample

Point of care testing (POCT) enables diagnostic tests to be performed rapidly while the patient remains at the point of care facility, such as a hospital, health clinic, doctor's office or another near-patient venue. POCT is rapidly being recognized as a method of providing the results of the diagnostic tests immediately, rather than waiting hours or even days for outside lab results to arrive, thus improving patient outcomes. This report analyzes the European market for POCT products, a major component of the overall European in vitro diagnostics (IVD) category. This study reviews in detail the key sub-segments of the point of care diagnostics market including: blood glucose, blood gas and electrolytes, rapid coagulation, cardiac markers, substance abuse, infectious diseases, urine strip, pregnancy, fecal occult, cholesterol, and many others. For each of the individual sub-segments, this study examines the key market drivers and restraints, as well as evaluates the latest technological advances. The key feature of the review is a detailed analysis of the revenues, market growth rates and market share for the European market and for each of the selected geographic regions, which include: France, Germany, Italy, Spain, the U.K., the Benelux countries, Scandinavia and the Rest of Europe (ROE). The analysis surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the point of care market in the European market. Each company is discussed in extensive depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position. Detailed tables and charts with sales forecasts and market data are also included.

 

TABLE OF CONTENTS

 

1. Overview 10
1.1 About This Report 10
1.2 Scope of this Report 10
1.3 Methodology 11
1.4 Executive Summary 13

2. Background to the European Market for Point of Care Testing (POCT) 17
2.1 Background and Definition of Point of Care Testing 17
2.2 POCT Application Areas 17
2.2.1 POCT in the Primary Care Environment 17
2.2.2 POCT in the Operating Room 18
2.2.3 POCT in the Intensive Care Unit (ICU) 18
2.2.4 POCT in Accident and Emergency (A&E) 18
2.2.5 POCT in the Patient Transport Setting 18
2.2.6 POCT in the Home Environment 18
2.2.7 POCT in the Community 19
2.2.8 POCT in Sports Medicine 19
2.2.9 POCT in the Physician’s Office Laboratory (POL)/Home Care Clinic 19
2.3 Qualitative Market Analysis 19
2.3.1 Market Drivers 19
2.3.2 Market Restraints 21
2.3.3 Advantages of POCT 23
2.3.4 Disadvantages of POCT 23
2.4 Regulatory Environment, Issues and Challenges 24
2.5 Overview of the European Healthcare Systems 27
2.6 Procurement Process of Point of Care Testing Products 29
2.7 Secondary Care Structure and Organization within the E.U. 31
2.8 Product Pricing Policy and Issues 35
2.9 Technological Advances and Developments 35
2.9.1 Device Miniaturization and Microfluidic Technologies 35
2.9.2 Minimally Invasive and Non-Invasive POCT Technologies 35
2.9.3 Advances in Wireless Technologies 36
2.9.4 Automation of POCT 36
2.9.5 Developments in New Genomic Technologies (Genotyping, Haplotyping and Sequencing
Technologies) 36
2.9.6 Advances in Informatics Technologies 38
2.9.7 Pharmacogenetic Testing 39
2.9.8 Multi Assay Technologies in POCT 39
2.10 Future Trends and Developments 40

3. The European Market for Blood Glucose POCT 41
3.1 Background to POC Blood Glucose Testing 41
3.2 Types of Blood Glucose Testing 42
3.2.1 Fasting Blood Sugar (FBS) or Fasting Plasma Glucose (FPG) 42
3.2.2 Two-Hour Postprandial Blood Sugar or Two-Hour PC 42
3.2.3 Random Blood Sugar (RBS) 42
3.2.4 Urine Glucose Test 42
3.2.5 Blood Glucose Test Strip 42
3.2.6 Glycosylated Hemoglobin (HbA1C) 43
3.2.7 Intravenous Glucose Tolerance Test (IVGTT) 43
3.2.8 Oral Glucose Tolerance Test (OGTT) 43
3.3 Segmentation of POC Blood Glucose Testing 43
3.3.1 Continuous Blood Glucose Monitoring (CBGM) 43
3.3.2 Self-Monitoring Blood Glucose (SMBG) Testing 44
3.3.3 Minimally Invasive and Non-Invasive Blood Glucose Testing 44
3.4 Emerging Glucose Monitoring Technologies 44
3.4.1 Optical Transducer Technologies 45
3.4.2 Transdermal Sensor Technologies 46
3.4.3 Invasive Glucose Sensor Technologies 47
3.5 Review of Selected POC Blood Glucose Monitoring Systems 47
3.6 Market Revenue Analysis 51
3.6.1 European Market Revenues Analysis 51
3.6.2 National Market Revenue Analysis 52
3.7 Market Share Analysis 53
3.7.1 European Market Share Analysis 53
3.7.2 European Market Share Analysis 54

4. The European Market for Blood Gas and Electrolyte POCT 58
4.1 Background to POC Blood Gas and Electrolyte Testing 58
4.1.1 Acid-base Balance and the Lungs 58
4.1.2 Respiratory Acidosis 58
4.1.3 Respiratory Alkalosis 58
4.1.4 Metabolic (or Non-Respiratory) Acidosis 58
4.1.5 Metabolic (or Non-Respiratory) Alkalosis 59
4.1.6 Increasing Popularity of POC Blood Gas and Electrolyte Testing 59
4.2 Market Segmentation 59
4.2.1 Types of Blood Gas Monitoring Equipment 59
4.2.1.1 Intermittent Blood Gas Monitoring Equipment 59
4.2.1.2 Continuous Blood Gas Monitoring Equipment 59
4.2.1.2.1 Extra-Arterial Blood Gas (EABG) Monitors 60
4.2.1.2.2 Intra-Arterial Blood Gas (IABG) Monitors 60
4.2.1.3 Portable, Blood Gas Analyzers 61
4.2.1.4 Patient Attached, On-Demand Blood Gas Analyzers 61
4.3 Applications for POCT Blood Gas and Electrolyte Analyzers 61
4.4 Qualitative Analysis 61
4.4.1 Market Drivers 61
4.4.2 Market Restraints 62
4.5 Emerging Technologies 62
4.6 Review of Selected Blood Gas and Electrolyte Analyzers 62
4.7 Market Revenue Analysis 64
4.7.1 European Market Revenues Analysis 64
4.7.2 National Market Revenue Analysis 65
4.8 Market Share Analysis 65
4.8.1 European Market Share Analysis 65
4.8.2 National Market Share Analysis 66

5. The European Market for Rapid Coagulation Testing 70
5.1 Background to Rapid Coagulation Testing 70
5.1.1 Hemostasis 70
5.1.2 Coagulation 70
5.1.2.1 The Intrinsic Pathway 71
5.1.2.2 The Extrinsic Pathway 71
5.1.3 Activation of Prothrombin to Thrombin 73
5.2 Blood Coagulation Tests 73
5.2.1 Bleeding Time Tests 73
5.2.2 Thrombin Time 74
5.2.3 The Prothrombin Time (PT) Test 74
5.2.4 The Partial Thromboplastin Time (PPT) Test 74
5.2.5 The Fibrinogen Test 75
5.2.6 Standard Test Results 76
5.3 Qualitative Analysis 76
5.3.1 Market Drivers 76
5.3.2 Market Restraints 77
5.4 Review of Selected POC Rapid Coagulation Analyzers 77
5.5 Market Revenue Analysis 79
5.5.1 European Market Revenue Analysis 79
5.5.2 National Market Revenue Analysis 80
5.6 Market Share Analysis 81
5.6.1 European Market Share Analysis 81
5.6.2 National Market Share Analysis 81

6. The European Market for POC Cardiac BioMarker Testing 85
6.1 Background to POC Cardiac Markers Testing 85
6.2 Cardiac Marker Tests 85
6.2.1 Creatine Kinase (CK) 85
6.2.2 Myoglobin 86
6.2.3 Cardiac Troponins T (TnT), I (TnI) and C (TnC) 86
6.2.4 C-reactive Protein (CRP) 86
6.2.5 Homocysteine 87
6.3 Emerging Markers 87
6.3.1 B-type Natriuretic Peptide (BNP) 87
6.3.2 Myeloperoxidase (MPO) 87
6.3.3 Ischemia Modified Albumin (IMA) 88
6.3.4 Glycogen Phosphorylase Isoenzyme BB (GPBB) 88
6.3.5 Fatty Acid-Binding Proteins (FABPs) 88
6.4 Qualitative Analysis 89
6.4.1 Market Drivers 89
6.4.2 Market Restraints 89
6.5 Review of Selected POC Cardiac Biomarkers Analyzers 90
6.6 Market Revenue Analysis 91
6.6.1 European Market Revenue Analysis 91
6.6.2 National Market Revenue Analysis 92
6.7 Market Share Analysis 93
6.7.1 European Market Share Analysis 93
6.7.2 National Market Share Analysis 94

7. The European Market for POC Substance Abuse Testing 98
7.1 Background to POC Substance Abuse Testing 98
7.2 Substance Abuse Test Types 100
7.2.1 Urine Substance/Drug Screening 100
7.2.2 Hair Tests for Substance Abuse and Screening 101
7.2.3 Blood Tests for Substance Abuse and Screening 101
7.2.4 Saliva Tests for Substance Abuse and Screening 101
7.2.5 Sweat Tests for Substance Abuse and Screening 101
7.2.6 Alcohol Abuse and Screening 101
7.3 Qualitative Analysis 102
7.3.1 Market Drivers 102
7.3.2 Market Restraints 103
7.4 Review of Selected POC Substance Abuse Analyzers 103
7.5 Market Revenue Analysis 105
7.5.1 European Market Revenue Analysis 105
7.5.2 National Market Revenue Analysis 105
7.6 Market Share Analysis 106
7.6.1 European Market Share Analysis 106
7.6.2 National Market Share Analysis 107

8. The European Market for POC Infectious Disease Testing 111
8.1 Background to POC Infectious Disease Testing 111
8.2 Types of Diagnosis for Infectious Diseases 112
8.2.1 Microbial Culture 112
8.2.2 Microscopy 112
8.2.3 Biochemical Tests 112
8.2.4 Molecular Diagnostics 112
8.3 Diagnostic Platforms for Infectious Diseases 113
8.3.1 Centralized Laboratory Testing for Infectious Diseases 113
8.3.2 POC Testing for Infectious Diseases 113
8.4 Emerging Technologies 114
8.5 Qualitative Analysis 114
8.5.1 Market Drivers 114
8.5.2 Market Restraints 115
8.6 Review of Selected POC Infectious Disease Testing Devices 115
8.7 Market Revenue Analysis 117
8.7.1 European Market Revenue Analysis 117
8.7.2 National Market Revenue Analysis 118
8.8 Market Share Analysis 118
8.8.1 European Market Share Analysis 118
8.8.2 National Market Share Analysis 119

9. The European Market for POC Urine Strip Testing 123
9.1 Background to POC Urine Strip Testing 123
9.2 Emerging Technologies 125
9.3 Review of Selected POC Urine Strip Testing 125
9.4 Market Revenue Analysis 127
9.4.1 European Market Revenue Analysis 127
9.4.2 National Market Revenue Analysis 128
9.5 Market Share Analysis 128
9.5.1 European Market Share Analysis 128
9.5.2 National Market Share Analysis 129

10. The European Market for POC Pregnancy Testing 132
10.1 Background to POC Pregnancy Testing 132
10.2 Review of Selected POC Pregnancy Testing Devices 132
10.3 Market Revenue Analysis 134
10.3.1 European Market Revenue Analysis 134
10.3.2 National Market Revenue Analysis 134
10.4 Market Share Analysis 135
10.4.1 European Market Share Analysis 135
10.4.2 National Market Share Analysis 136

11. The European Market for POC Fecal Occult Testing 139
11.1 Background to POC Fecal Occult Testing 139
11.2 Review of Selected POC Fecal Occult Testing Devices 140
11.3 Market Revenue Analysis 142
11.3.1 European Market Revenue Analysis 142
11.3.2 National Market Revenue Analysis 143
11.4 Market Share Analysis 144
11.4.1 European Market Share Analysis 144
11.4.2 National Market Share Analysis 144

12. The European Market for POC Cholesterol Testing 147
12.1 Background to POC Cholesterol Testing 147
12.2 POC Cholesterol Testing Devices 148
12.2.1 Review of Selected POC Cholesterol Testing Devices 148
12.2.2 Product Comparison of Leading Suppliers 149
12.2.3 Launch Dates of Leading Products in Europe 152
12.3 Market Revenue Analysis 152
12.3.1 European Market Revenue Analysis 152
12.3.2 National Market Revenue Analysis 153
12.4 Market Share Analysis 153
12.4.1 European Market Share Analysis 153
12.4.2 National Market Share Analysis 154

13. Profile of Leading Suppliers 157
13.1 Abaxis, Inc. 157
13.2 Abbott Laboratories 159
13.3 ACON Laboratories, Inc. 161
13.4 AgaMatrix, Inc. 161
13.5 Alere, Inc. 162
13.6 Bayer AG 164
13.7 LifeScan (Johnson & Johnson) 166
13.8 International Technidyne Corporation (ITC) Nexus Dx (Warburg Pincus, LLC) 167
13.9 NOVA Biomedical 168
13.10 F. Hoffman-La Roche Ltd. 168
13.11 A Menarini Diagnostics 170
13.12 Medtronic, Inc. 171
13.13 Radiometer Medical (Danaher Corporation) 172
13.14 Instrumentation Laboratory (IL)/Werfen Group 174
13.15 Siemens 174

14. Glossary of Abbreviations and Acronyms 176


INDEX OF FIGURES

Figure 2.1: Available forms of Connectivity Technology for POCT Devices 22
Figure 2.2: Conformity Assessment Route, Annexes and Quality System Standards by IVD
Device Category 25
Figure 5.1: The Coagulation Cascade 72
Figure 5.2: Coagulation Testing 75


INDEX OF TABLES

Table 1.1: European Revenue Analysis and Forecasts for POC Market, 2007-2017 13
Table 1.2: Segment Revenue Analysis and Forecasts for POC Market, 2007-2017 14
Table 1.3: European Revenue Forecasts for POC Market, 2007-2017 15
Table 1.4: European Market Share Analysis for POC Market, 2010 16
Table 2.1: Total Expenditure on Healthcare, Percentage GDP of Selected Countries, 2002-2008 28
Table 2.2: Models of Public-Private Partnership in Hospital Provision 32
Table 2.3: Common Genotype Techniques 37
Table 3.1: Summary of Emerging Glucose Sensor Technologies, 2011 46
Table 3.2: Selected POC Blood Glucose Monitoring Systems, 2011 48
Table 3.3: European Revenue Forecasts for POC Blood Glucose Monitoring Systems, 2007-2017 52
Table 3.4: National Revenue Forecasts by Country for POC Blood Glucose Monitoring Systems,
2007-2017 53
Table 3.5: European Market Share Analysis for POC Blood Glucose Monitoring Systems, 2010 54
Table 3.6: French Market Share Analysis for POC Blood Glucose Monitoring Systems, 2010 54
Table 3.7: German Market Share Analysis for POC Blood Glucose Monitoring Systems, 2010 55
Table 3.8: Italian Market Share Analysis for POC Blood Glucose Monitoring Systems, 2010 55
Table 3.9: Spanish Market Share Analysis for POC Blood Glucose Monitoring Systems, 2010 55
Table 3.10: U.K. Market Share Analysis for POC Blood Glucose Monitoring Systems, 2010 56
Table 3.11: Benelux Market Share Analysis for POC Blood Glucose Monitoring Systems, 2010 56
Table 3.12: Scandinavian Market Share Analysis for POC Blood Glucose Monitoring Systems, 2010 56
Table 3.13: Rest-of-Europe Market Share Analysis for POC Blood Glucose Monitoring Systems, 2010 57
Table 4.1: Selected POC Blood Gas and Electrolyte Analyzers, 2011 63
Table 4.2: European Revenue Forecasts for POC Blood Gas Analysis Systems, 2007-2017 64
Table 4.3: National Revenue Forecasts by Country for POC Blood Gas Analysis Systems, 2007-2017 65
Table 4.4: European Market Share Analysis for POC Blood Gas Analysis Systems, 2010 66
Table 4.5: French Market Share Analysis for POC Blood Gas Analysis Systems, 2010 67
Table 4.6: German Market Share Analysis for POC Blood Gas Analysis Systems, 2010 67
Table 4.7: Italian Market Share Analysis for POC Blood Gas Analysis Systems, 2010 67
Table 4.8: Spanish Market Share Analysis for POC Blood Gas Analysis Systems, 2010 68
Table 4.9: U.K. Market Share Analysis for POC Blood Gas Analysis Systems, 2010 68
Table 4.10: Benelux Market Share Analysis for POC Blood Gas Analysis Systems, 2010 68
Table 4.11: Scandinavian Market Share Analysis for POC Blood Gas Analysis Systems, 2010 69
Table 4.12: Rest-of-Europe Market Share Analysis for POC Blood Gas Analysis Systems, 2010 69
Table 5.1: Selected POC Rapid Coagulation Analyzers, 2011 77
Table 5.2: European Revenue Forecasts for POC Rapid Coagulation Analyzer Systems, 2007-2017 80
Table 5.3: National Revenue Forecasts by Country for POC Rapid Coagulation Analyzer Systems,
2007-2017 80
Table 5.4: European Market Share Analysis for POC Rapid Coagulation Analyzer Systems, 2010 81
Table 5.5: French Market Share Analysis for POC Rapid Coagulation Analyzer Systems, 2010 82
Table 5.6: German Market Share Analysis for POC Rapid Coagulation Analyzer Systems, 2010 82
Table 5.7: Italian Market Share Analysis for POC Rapid Coagulation Analyzer Systems, 2010 82
Table 5.8: Spanish Market Share Analysis for POC Rapid Coagulation Analyzer Systems, 2010 83
Table 5.9: U.K. Market Share Analysis for POC Rapid Coagulation Analyzer Systems, 2010 83
Table 5.10: Benelux Market Share Analysis for POC Rapid Coagulation Analyzer Systems, 2010 83
Table 5.11: Scandinavian Market Share Analysis for POC Rapid Coagulation Analyzer Systems, 2010 84
Table 5.12: Rest-of-Europe Market Share Analysis for POC Rapid Coagulation Analyzer Systems, 2010 84
Table 6.1: Selected POC Cardiac Biomarkers, 2011 90
Table 6.2: European Revenue Forecasts for POC Cardiac Marker Devices, 2007-2017 92
Table 6.3: National Revenue Forecasts by Country for POC Cardiac Marker Devices, 2007-2017 92
Table 6.4: European Market Share Analysis for POC Cardiac Marker Devices, 2010 94
Table 6.5: French Market Share Analysis for POC Cardiac Marker Devices, 2010 94
Table 6.6: German Market Share Analysis for POC Cardiac Marker Devices, 2010 95
Table 6.7: Italian Market Share Analysis for POC Cardiac Marker Devices, 2010 95
Table 6.8: Spanish Market Share Analysis for POC Cardiac Marker Devices, 2010 95
Table 6.9: U.K. Market Share Analysis for POC Cardiac Marker Devices, 2010 96
Table 6.10: Benelux Market Share Analysis for POC Cardiac Marker Devices, 2010 96
Table 6.11: Scandinavian Market Share Analysis for POC Cardiac Marker Devices, 2010 96
Table 6.12: Rest-of-Europe Market Share Analysis for POC Cardiac Marker Devices, 2010 97
Table 7.1: Selected POC Substance/Drug Abuse Testing Devices, 2011 103
Table 7.2: European Revenue Forecasts for POC Substance/Drug Abuse Testing Device Market,
2007-2017 105
Table 7.3: National Revenue Forecasts by Country for POC Substance/Drug Abuse Testing Device Market,
2007-2017 106
Table 7.4: European Market Share Analysis for POC Substance/Drug Abuse Testing Device Market, 2010 107
Table 7.5: French Market Share Analysis for POC Substance/Drug Abuse Testing Device Market, 2010 107
Table 7.6: German Market Share Analysis for POC Substance/Drug Abuse Testing Device Market, 2010 108
Table 7.7: Italian Market Share Analysis for POC Substance/Drug Abuse Testing Device Market, 2010 108
Table 7.8: Spanish Market Share Analysis for POC Substance/Drug Abuse Testing Device Market, 2010 108
Table 7.9: U.K. Market Share Analysis for POC Substance/Drug Abuse Testing Device Market, 2010 109
Table 7.10: Benelux Market Share Analysis for POC Substance/Drug Abuse Testing Device Market, 2010 109
Table 7.11: Scandinavian Market Share Analysis for POC Substance/Drug Abuse Testing Device Market,
2010 109
Table 7.12: Rest-of-Europe Market Share Analysis for POC Substance/Drug Abuse Testing Device Market,
2010 110
Table 8.1: Selected POC Infectious Disease Testing Devices, 2011 115
Table 8.2: European Revenue Forecasts for POC Infectious Disease Testing Devices Market, 2007-2017 117
Table 8.3: National Revenue Forecasts by Country for POC Infectious Disease Testing Devices Market,
2007-2017 118
Table 8.4: European Market Share Analysis for POC Infectious Disease Testing Devices, 2010 119
Table 8.5: French Market Share Analysis for POC Infectious Disease Testing Devices, 2010 119
Table 8.6: German Market Share Analysis for POC Infectious Disease Testing Devices, 2010 120
Table 8.7: Italian Market Share Analysis for POC Infectious Disease Testing Devices, 2010 120
Table 8.8: Spanish Market Share Analysis for POC Infectious Disease Testing Devices, 2010 120
Table 8.9: U.K. Market Share Analysis for POC Infectious Disease Testing Devices, 2010 121
Table 8.10: Benelux Market Share Analysis for POC Infectious Disease Testing Devices, 2010 121
Table 8.11: Scandinavian Market Share Analysis for POC Infectious Disease Testing Devices, 2010 122
Table 8.12: Rest-of-Europe Market Share Analysis for POC Infectious Disease Testing Devices, 2010 122
Table 9.1: Selected POC Urine Strip Testing, 2011 126
Table 9.2: European Revenue Forecasts for POC Urine Strip Testing Products Market, 2007-2017 127
Table 9.3: National Revenue Forecasts by Country for POC Urine Strip Testing Products Market,
2007-2017 128
Table 9.4: European Market Share Analysis for POC Urine Strip Testing Products, 2010 129
Table 9.5: French Market Share Analysis for POC Urine Strip Testing Products, 2010 129
Table 9.6: German Market Share Analysis for POC Urine Strip Testing Products, 2010 129
Table 9.7: Italian Market Share Analysis for POC Urine Strip Testing Products, 2010 130
Table 9.8: Spanish Market Share Analysis for POC Urine Strip Testing Products, 2010 130
Table 9.9: U.K. Market Share Analysis for POC Urine Strip Testing Products, 2010 130
Table 9.10: Benelux Market Share Analysis for POC Urine Strip Testing Products, 2010 131
Table 9.11: Scandinavian Market Share Analysis for POC Urine Strip Testing Products, 2010 131
Table 9.12: Rest-of-Europe Market Share Analysis for POC Urine Strip Testing Products, 2010 131
Table 10.1: Selected POC Pregnancy Testing Devices, 2011 133
Table 10.2: European Revenue Forecasts for POC Pregnancy Testing Devices Market, 2007-2017 134
Table 10.3: National Revenue Forecasts by Country for POC Pregnancy Testing Devices Market,
2007-2017 135
Table 10.4: European Market Share Analysis for POC Pregnancy Testing Devices, 2010 136
Table 10.5: French Market Share Analysis for POC Pregnancy Testing Devices, 2010 136
Table 10.6: German National Market Share Analysis for POC Pregnancy Testing Devices, 2010 136
Table 10.7: Italian Market Share Analysis for POC Pregnancy Testing Devices, 2010 137
Table 10.8: Spanish Market Share Analysis for POC Pregnancy Testing Devices, 2010 137
Table 10.9: U.K. Market Share Analysis for POC Pregnancy Testing Devices, 2010 137
Table 10.10: Benelux Market Share Analysis for POC Pregnancy Testing Devices, 2010 138
Table 10.11: Scandinavian Market Share Analysis for POC Pregnancy Testing Devices, 2010 138
Table 10.12: Rest-of-Europe Market Share Analysis for POC Pregnancy Testing Devices, 2010 138
Table 11.1: Selected POC Fecal Occult Testing Devices, 2011 141
Table 11.2: European Revenue Forecasts for POC Fecal Occult Testing Devices Market, 2007-2017 143
Table 11.3: National Revenue Forecasts by Country for POC Fecal Occult Testing Devices Market,
2007-2017 143
Table 11.4: European Market Share Analysis for POC Fecal Occult Testing Devices, 2010 144
Table 11.5: French Market Share Analysis for POC Fecal Occult Testing Devices, 2010 145
Table 11.6: German Market Share Analysis for POC Fecal Occult Testing Devices, 2010 145
Table 11.7: Italian Market Share Analysis for POC Fecal Occult Testing Devices, 2010 145
Table 11.8: Spanish Market Share Analysis for POC Fecal Occult Testing Devices, 2010 145
Table 11.9: U.K. Market Share Analysis for POC Fecal Occult Testing Devices, 2010 146
Table 11.10: Benelux Market Share Analysis for POC Fecal Occult Testing Devices, 2010 146
Table 11.11: Scandinavian Market Share Analysis for POC Fecal Occult Testing Devices, 2010 146
Table 11.12: Rest-of-Europe Market Share Analysis for POC Fecal Occult Testing Devices, 2010 146
Table 12.1: Selected POC Cholesterol Testing Devices, 2011 149
Table 12.2: European Revenue Forecasts for POC Cholesterol Testing Products Market, 2007-2017 152
Table 12.3: National Revenue Forecasts by Country for POC Cholesterol Testing Products Market,
2007-2017 153
Table 12.4: European Market Share Analysis for POC Cholesterol Testing Products Market, 2010 154
Table 12.5: French Market Share Analysis for POC Cholesterol Testing Products Market, 2010 154
Table 12.6: German Market Share Analysis for POC Cholesterol Testing Products Market, 2010 154
Table 12.7: Italian Market Share Analysis for POC Cholesterol Testing Products Market, 2010 155
Table 12.8: Spanish Market Share Analysis for POC Cholesterol Testing Products Market, 2010 155
Table 12.9: U.K. Market Share Analysis for POC Cholesterol Testing Products Market, 2010 155
Table 12.10: Benelux Market Share Analysis for POC Cholesterol Testing Products Market, 2010 156
Table 12.11: Scandinavian Market Share Analysis for POC Cholesterol Testing Products Market, 2010 156
Table 12.12: Rest-of-Europe Market Share Analysis for POC Cholesterol Testing Products Market, 2010 156
Table 13.1: Abaxis, Inc. Net Sales by Business Sector, 2008-2010 158
Table 13.2: Abaxis, Inc. Net Sales by Geographic Region, 2008-2010 159
Table 13.3: Abbott Laboratories Net Sales by Business Sector, 2008-2010 160
Table 13.4: Abbott Laboratories Net Sales by Geographic Region, 2008-2010 160
Table 13.5: Alere, Inc. Net Sales by Business Sector, 2008-2010 164
Table 13.6: Alere, Inc. Net Sales by Geographic Region, 2008-2010 164
Table 13.7: Bayer AG Net Sales by Business Sector, 2008-2010 165
Table 13.8: Bayer AG Net Sales by Geographic Region, 2008-2010 165
Table 13.9: Johnson & Johnson Net Sales by Major Medical and Diagnostics Businesses, 2008-2010 167
Table 13.10: Roche Group Net Sales by Business Sector, 2008-2010 169
Table 13.11: Roche Group Net Sales by Geographic Region (Pharmaceuticals), 2009 and 2010 170
Table 13.12: Roche Group Net Sales by Sub-Division (Diagnostics), 2008-2010 170
Table 13.13: Medtronic Net Sales by Segment, 2008-2010 172
Table 13.14: Danaher Corporation Net Sales by Business Sector, 2008-2010 173
Table 13.15: Danaher Corporation Net Sales by Geographic Region, 2008-2010 173

Find Similar Products by Category